<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31467" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Zileuton</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bouchette</surname>
            <given-names>Daniel</given-names>
          </name>
          <aff>St.Martinus Faculty of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Bouchette declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31467.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Zileuton, a 5-lipoxygenase inhibitor, is a primary intervention for the prophylaxis and treatment of chronic asthma in patients aged 12 and older. Although zileuton is frequently administered in conjunction with inhaled corticosteroids&#x000a0;for chronic asthma, it is not effective for managing acute asthma attacks.&#x000a0;</p>
        <p>Zileuton is also used off-label in patients with aspirin-induced asthma. The application of the drug extends to aspirin-induced asthma, with research supporting its efficacy in chronic obstructive pulmonary disease and dermatological conditions such as acne, pruritic manifestations in Sj&#x000f6;gren-Larsson syndrome, and atopic dermatitis. This activity delves into the complexities of clinical toxicity, drug interactions, pharmacokinetics, and the importance of vigilant monitoring while administering zileuton to patients. This activity equips the interprofessional healthcare team with the necessary skills to manage diverse clinical scenarios and&#x000a0;improve&#x000a0;patient care in the context of respiratory and dermatological conditions&#x000a0;using zileuton effectively.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for zileuton therapy based on their age (12 and older) and a diagnosis of chronic asthma.</p></list-item><list-item><p>Implement vigilant monitoring protocols for patients receiving zileuton, considering clinical toxicity, drug interactions, and pharmacokinetics.</p></list-item><list-item><p>Select optimal combinations of zileuton with other medications for patients with chronic myeloid leukemia or aspirin-exacerbated respiratory disease.</p></list-item><list-item><p>Collaborate with the interprofessional healthcare team to coordinate comprehensive patient care, integrating zileuton appropriately into treatment plans.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31467&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31467">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31467.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Zileuton is a 5-lipoxygenase inhibitor approved by the United States Food and Drug Administration (FDA) for the prophylaxis and treatment of chronic asthma in patients aged 12 and older.<xref ref-type="bibr" rid="article-31467.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indication</bold>
</p>
        <p>Zileuton is a primary intervention for the prophylaxis and treatment of chronic asthma in patients aged 12 or older. Although zileuton is frequently administered in conjunction with inhaled corticosteroids&#x000a0;for chronic asthma, it is not effective for managing acute asthma attacks.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Zileuton is also used off-label in patients with aspirin-induced asthma.<xref ref-type="bibr" rid="article-31467.r2">[2]</xref>&#x000a0;Research supports the effectiveness of zileuton in treating patients with chronic obstructive pulmonary disease, upper airway inflammatory conditions, and dermatological conditions such as acne, pruritus in Sj&#x000f6;gren-Larsson syndrome, and atopic dermatitis.<xref ref-type="bibr" rid="article-31467.r3">[3]</xref>&#x000a0;</p>
        <p>Studies have demonstrated that individuals with exercise-induced asthma can derive benefits from the drug when administered 1 hour before exercise. In addition, zileuton&#x000a0;has shown efficacy in inhibiting chronic myeloid leukemia, whether combined with imatinib or as a standalone treatment.<xref ref-type="bibr" rid="article-31467.r4">[4]</xref> A recent study has also indicated that zileuton&#x000a0;may decrease the necessity for sinus surgeries in aspirin-exacerbated respiratory disease.<xref ref-type="bibr" rid="article-31467.r5">[5]</xref>&#x000a0;In addition, a topical formulation of zileuton&#x000a0;is currently under investigation for treating atopic dermatitis<bold>.</bold><xref ref-type="bibr" rid="article-31467.r6">[6]</xref> Clinicians are advised to conduct a thorough risk-benefit analysis before considering using zileuton for off-label indications.</p>
      </sec>
      <sec id="article-31467.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Currently, 2&#x000a0;primary approaches to leukotriene inhibition are recognized. One approach is antagonistic blockage of cys-LT1 receptors from cysteinyl leukotrienes on bronchial smooth muscle cells, which is the mechanism of action for montelukast and zafirlukast.<xref ref-type="bibr" rid="article-31467.r7">[7]</xref><xref ref-type="bibr" rid="article-31467.r8">[8]</xref><xref ref-type="bibr" rid="article-31467.r9">[9]</xref>&#x000a0;The second approach is the inhibition of 5-lipoxygenase. The enzyme 5-lipoxygenase is necessary for the biosynthesis of leukotrienes. Zileuton is a 5-lipoxygenase inhibitor that inhibits the formation of leukotrienes B4, C4, D4, and E4. Limiting these leukotrienes helps reduce inflammation, edema, mucus secretion, and bronchoconstriction in the airways. This action reduces leukocyte adhesion, smooth muscle contraction, capillary permeability, and the migration and aggregation of neutrophils and eosinophils. Consequently, a reduction in asthma exacerbations is evidenced by improving asthma symptoms.<xref ref-type="bibr" rid="article-31467.r3">[3]</xref>&#x000a0;</p>
        <p>Recent research suggests that&#x000a0;the phosphatidylinositide 3-kinase (PI3K) pathway is a major determinant of clinical response to Zileuton&#x000a0;patients with asthma. Patients showing poor response to zileuton have increased activation of PIK3CA, resulting in increased leukotriene B4&#x000a0;production&#x000a0;and resistance to Zileuton therapy. Higher concentrations of leukotriene-B4&#x000a0;can bind to GPCR, leading to increased PIK3CA signaling and proliferation of pro-inflammatory responses mediated by leukotriene activity. In contrast, patients with&#x000a0;positive responses would have limited leukotriene B4&#x000a0;production following Zileuton treatment.<xref ref-type="bibr" rid="article-31467.r10">[10]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> According to the manufacturer's labeling, zileuton is rapidly absorbed upon oral administration, and peak plasma concentration is attained in approximately 1.7 hours.</p>
        <p><bold>Distribution:</bold>&#x000a0;Zileuton has an apparent volume of distribution of approximately 1.2 L/kg. Zileuton has high plasma protein binding (93%). It is primarily bound to albumin; a small proportion is bound to &#x003b1;-1-acid glycoprotein.</p>
        <p><bold>Metabolism:</bold> Zileuton is primarily metabolized in the liver by the cytochrome P450 system, including CYP1A2, CYP2C9, and CYP3A4. Zileuton's metabolites include&#x000a0;2 glucuronide conjugates (significant metabolites) and an <italic toggle="yes">N</italic>-dehydroxylated metabolite. Pharmacodynamic activity is primarily due to the parent drug.</p>
        <p><bold>Elimination:</bold> Zileuton and its metabolites are primarily excreted in the urine (94.5%). The mean terminal half-life of zileuton&#x000a0;is 2.5 hours.<xref ref-type="bibr" rid="article-31467.r11">[11]</xref></p>
      </sec>
      <sec id="article-31467.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Zileuton is only available in a tablet formulation. The tablets are single-strength, 600 mg white, oval, and film-coated. Zileuton should be stored at room temperature 20 &#x000b0;C to 25 &#x000b0;C (68 &#x000b0;F to 77 &#x000b0;F).<xref ref-type="bibr" rid="article-31467.r12">[12]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Administer&#x000a0;2 (600 mg) extended-release tablets twice daily. Administer immediate-release (IR) tablets of 600 mg&#x000a0;4 times daily.&#x000a0;<xref ref-type="bibr" rid="article-31467.r13">[13]</xref>&#x000a0;Use within&#x000a0;1 hour of morning and evening meals.&#x000a0;Zileuton can&#x000a0;be used in conjunction with inhaled corticosteroids. These tablets should not be crushed, split in half, or chewed. Patients should not use this drug for acute asthma attacks. In addition, patients should not take a double dose if they miss a scheduled drug dose.&#x000a0;Patients are advised not to change the dosage of any other anti-asthma medication unless told by a&#x000a0;clinician. Zileuton is not the preferred medication in GINA (Global Initiative for Asthma) guidelines. However, a&#x000a0;study suggests that Zileuton response varies across asthmatics, with&#x000a0;low response rates associated with those with severe asthma and obesity.&#x000a0;Consequently, Zileuton and leukotriene receptor antagonists (like Montelukast) could be considered for non-severe asthma.<xref ref-type="bibr" rid="article-31467.r14">[14]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:&#x000a0;</bold>Dose adjustment in patients with renal&#x000a0;impairment or hemodialysis is not&#x000a0;required.</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Zileuton is contraindicated in patients with active liver disease or constant ALT elevations &#x02265;3 upper limits of normal. Hepatic injury due to zileuton has been self-limited, but the possibility of severe injury and hepatic failure must be evaluated, especially if the medication is not stopped.<xref ref-type="bibr" rid="article-31467.r13">[13]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Severe asthma exacerbations, particularly during the first trimester of pregnancy, are&#x000a0;associated with an increased&#x000a0;risk of congenital malformations.&#x000a0;According to GINA guidelines, pregnant patients should be suggested that poorly controlled asthma and exacerbations expose their&#x000a0;infants to a much greater risk than&#x000a0;pharmacological treatments. Zileuton is a former FDA pregnancy category C drug. Zileuton&#x000a0;should be used during pregnancy only after carefully considering the risk-benefit analysis. Other&#x000a0;agents are preferred as controller and reliever medications.<xref ref-type="bibr" rid="article-31467.r15">[15]</xref><xref ref-type="bibr" rid="article-31467.r16">[16]</xref><xref ref-type="bibr" rid="article-31467.r17">[17]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>No&#x000a0;medical&#x000a0;information exists on using zileuton&#x000a0;during breastfeeding; however, the manufacturer's data indicate that the&#x000a0;concentration of zileuton in maternal milk is low. No published experience with zileuton&#x000a0;during breastfeeding is evidenced, so accordingly, an alternate drug&#x000a0;should be used, particularly while nursing a newborn or preterm infant.<xref ref-type="bibr" rid="article-31467.r18">[18]</xref></p>
        <p><bold>Pediatric patients:</bold> Zileuton is not FDA-approved for asthma management in pediatric patients aged 12 or younger.</p>
        <p><bold>Older&#x000a0;patients: </bold>Patients aged 65&#x000a0;or older taking Zileuton&#x000a0;IR are at a higher risk of developing elevated ALT levels.<xref ref-type="bibr" rid="article-31467.r19">[19]</xref></p>
      </sec>
      <sec id="article-31467.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Serum alanine aminotransferase (ALT) concentration must be obtained from the patient before the Zileuton treatment, as hepatotoxicity can occur. The pattern of liver injury is hepatocellular, and ALT is the most sensitive liver enzyme for liver injury with Zileuton treatments.<xref ref-type="bibr" rid="article-31467.r13">[13]</xref> Symptoms include jaundice, right upper abdominal pain, edema, or pruritus. If ALT concentration is normal, concentration must be monitored once a month for the first&#x000a0;3 months and then every&#x000a0;3 months for the year.<xref ref-type="bibr" rid="article-31467.r13">[13]</xref>&#x000a0;After that, they require periodic monitoring&#x000a0;when receiving long-term treatment. Discontinuation of the drug can cause a resolution of toxicity within 21 days. Patients with a history of liver disease or excessive alcohol&#x000a0;consumption should use zileuton cautiously.&#x000a0;Rechallenge of Zileuton should be avoided as it leads to the recurrence of hepatotoxicity.<xref ref-type="bibr" rid="article-31467.r18">[18]</xref><xref ref-type="bibr" rid="article-31467.r20">[20]</xref><xref ref-type="bibr" rid="article-31467.r21">[21]</xref></p>
        <p>Patients undergoing long-term therapy (eg, taking zileuton&#x000a0;for more than&#x000a0;6 months) may experience frequent headaches, upper respiratory tract infections, diarrhea, or myalgia. However, these symptoms are similar to placebo treatment in many cases, eg, headache: 25% for zileuton and 24% for placebo. In one study, dyspepsia was the most statistically significant&#x000a0;adverse&#x000a0;effect compared to the placebo group.<xref ref-type="bibr" rid="article-31467.r1">[1]</xref>&#x000a0;Other reported adverse events include sinusitis, nausea, headache, abdominal pain, or pharyngolaryngeal pain. Zileuton can infrequently cause a decrease in white blood cell count.&#x000a0;In most&#x000a0;cases, the white blood cell count returned to normal or baseline without changing the Zileuton treatment.<xref ref-type="bibr" rid="article-31467.r22">[22]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent use of Loxapine should be avoided due to the risk of severe bronchospasm.<xref ref-type="bibr" rid="article-31467.r23">[23]</xref>&#x000a0;CYP1A2 inhibitors like zileuton may&#x000a0;increase the serum concentration of Tizanidine and lead to&#x000a0;adverse reactions such as bradycardia and hypotension. Avoid concurrent administration.<xref ref-type="bibr" rid="article-31467.r24">[24]</xref>&#x000a0;Monitor liver function tests (LFT) and plasma concentrations of Theophylline, Warfarin, and Propranolol, as zileuton&#x000a0;can increase serum concentrations of these medications when taken simultaneously.<xref ref-type="bibr" rid="article-31467.r13">[13]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Studies have shown a 15% decrease in Warfarin clearance, significantly increasing prothrombin times. Therefore, the recommendation is to monitor prothrombin times if the patient takes Warfarin with Zileuton.<xref ref-type="bibr" rid="article-31467.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Research has shown that patients taking zileuton&#x000a0;IR tablets and Propranolol experienced an increase in serum&#x000a0;level concentration within&#x000a0;5 days, leading to bradycardia and the risk for hypotension. Therefore, patients taking Propranolol or other beta-blocking agents must be monitored or have their beta-blocker dose reduced to prevent complications.<xref ref-type="bibr" rid="article-31467.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent administration of theophylline&#x000a0;and zileuton&#x000a0;leads to a reduction in Theophylline clearance within&#x000a0;5 days. Clinicians should monitor the plasma concentrations of theophylline in patients and reduce the dosage accordingly.&#x000a0;Adjust the maintenance dose if the patient is already on zileuton.<xref ref-type="bibr" rid="article-31467.r27">[27]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31467.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Patients with active liver disease or a history of hypersensitivity to zileuton&#x000a0;or excipients&#x000a0;should not take the medication. When using zileuton, patients with ALT elevations more than&#x000a0;3 times the normal upper limit should avoid taking zileuton and consider a different therapy course.<xref ref-type="bibr" rid="article-31467.r28">[28]</xref><xref ref-type="bibr" rid="article-31467.r29">[29]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>Patients taking zileuton may experience sleep disorders or changes in behavior. If neuropsychiatric events occur, patients should contact their clinician.<xref ref-type="bibr" rid="article-31467.r30">[30]</xref>&#x000a0;No contraindications exist for use in pregnant patients. However, patients should not use zileuton unless the benefit to the mother justifies the risk to the fetus.<xref ref-type="bibr" rid="article-31467.r31">[31]</xref>&#x000a0;Clinicians should avoid prescribing zileuton to patients under 12 as its safety and effectiveness in the age group have not been established. Concerns in this group are primarily due to the risk of hepatotoxicity. Female patients aged over 65 must use zileuton cautiously as they are more susceptible to hepatotoxicity and liver injury.<xref ref-type="bibr" rid="article-31467.r19">[19]</xref></p>
      </sec>
      <sec id="article-31467.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitor liver function tests and plasma concentrations of theophylline, warfarin, and propranolol, as zileuton can increase serum concentrations of these medications when taken simultaneously.<xref ref-type="bibr" rid="article-31467.r13">[13]</xref>&#x000a0;Monitor for neuropsychiatric adverse drug reactions such as sleep disorders and behavior changes. Monitor pulmonary function tests (typically reversible obstructive pattern) in patients with asthma.<xref ref-type="bibr" rid="article-31467.r32">[32]</xref>&#x000a0;National Institute for Clinical Excellence guidelines&#x000a0;suggest&#x000a0;spirometry for monitoring asthma at each&#x000a0;clinic visit or at least after 3 or 6 months from the commencement of&#x000a0;treatment and afterward every 1 to 2 years.<xref ref-type="bibr" rid="article-31467.r32">[32]</xref>&#x000a0;Monitor estimated peak expiratory flow rate; measurements can be variable according to age, height, and race.<xref ref-type="bibr" rid="article-31467.r33">[33]</xref><xref ref-type="bibr" rid="article-31467.r34">[34]</xref>&#x000a0;Repeated peak flow measurement is simple to execute in clinical settings.<xref ref-type="bibr" rid="article-31467.r35">[35]</xref></p>
      </sec>
      <sec id="article-31467.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Overdose is treated based on symptoms with supportive care if a patient has signs of toxicity. Dialysis does not remove zileuton from the bloodstream. Treatment with gastric lavage may be necessary to eliminate any unabsorbed drug. Limited guidelines exist around the approach to overdose. According to product labeling, a case report of a patient taking between 6.6 and 9.0 g of zileuton and completely recovering without complications is reported. The clinician should consult a medical toxicologist or poison control center for up-to-date information on the management of zileuton overdose.&#x000a0;The American Association of Poison Control Centers and National Poison Data System research reinforces the importance of expertise and the need for specialized medical toxicology knowledge to manage drug overdose.<xref ref-type="bibr" rid="article-31467.r36">[36]</xref></p>
      </sec>
      <sec id="article-31467.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The interprofessional healthcare team, including the primary care clinicians, physician assistants, and nurse practitioners who prescribe zileuton, should be familiar with the drug's indications and contraindications. Zileuton is only used for prophylaxis of asthma and is not recommended for monotherapy. It also has several off-label uses. Clinicians should monitor the patient's liver function on zileuton regularly.&#x000a0;Nurses can monitor for&#x000a0;any&#x000a0;neuropsychiatric symptoms and report to the clinician team.<bold>&#x000a0;</bold>According to the CDC, moderate to severe asthma is a risk factor for severe COVID-19 infection.<xref ref-type="bibr" rid="article-31467.r37">[37]</xref>&#x000a0;Pharmacists can ensure the drug is dosed appropriately, check for interactions, and counsel patients on the proper use and administration of the medication.</p>
        <p>A pulmonologist or immunologist consultation may be required if asthma is uncontrolled despite optimal medical therapy. The Asthma Quality of Life Questionnaire can assess quality of life.<xref ref-type="bibr" rid="article-31467.r38">[38]</xref>&#x000a0;Zileuton&#x000a0;can interact with drugs like Warfarin, Theophylline, and Propranolol; therefore, a pharmacist should thoroughly review the patient's medication profile to prevent drug interactions. In an overdose of zileuton, a medical toxicologist and intensivist consultation are necessary. A psychiatrist consultation is also required if the overdose is intentional. All healthcare professionals, including clinicians, immunologists or pulmonologists, pharmacists, medical toxicologists, and nurses, should use interprofessional team strategies to improve care coordination and patient outcomes when using zileuton&#x000a0;for asthma.</p>
      </sec>
      <sec id="article-31467.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31467&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31467">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31467/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31467">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31467.s11">
        <title>References</title>
        <ref id="article-31467.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wenzel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kamada</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.</article-title>
            <source>Ann Pharmacother</source>
            <year>1996</year>
            <season>Jul-Aug</season>
            <volume>30</volume>
            <issue>7-8</issue>
            <fpage>858</fpage>
            <page-range>858-64</page-range>
            <pub-id pub-id-type="pmid">8826571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Farquhar</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Masood</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Senior</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Thorp</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Zanation</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ebert</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease.</article-title>
            <source>Am J Rhinol Allergy</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>791</fpage>
            <page-range>791-795</page-range>
            <pub-id pub-id-type="pmid">31483687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>De Chandt</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Cairns</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.</article-title>
            <source>Int J Clin Pract</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>663</fpage>
            <page-range>663-76</page-range>
            <pub-id pub-id-type="pmid">17394438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dolinska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piccini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Gelali</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Klang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yektaei-Karin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Str&#x000f6;mberg</surname>
                <given-names>UO</given-names>
              </name>
              <name>
                <surname>Mustjoki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stenke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ekblom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in&#x000a0;vitro growth of CD34<sup>+</sup>CD38<sup>-</sup> stem and progenitor cells in chronic myeloid leukemia.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>2017</year>
            <month>Aug</month>
            <day>19</day>
            <volume>490</volume>
            <issue>2</issue>
            <fpage>378</fpage>
            <page-range>378-384</page-range>
            <pub-id pub-id-type="pmid">28623130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Makary</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Unsal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Munjal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kountakis</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Long-term role of zileuton in the treatment of chronic rhinosinusitis in aspirin exacerbated respiratory disease.</article-title>
            <source>Am J Otolaryngol</source>
            <year>2022</year>
            <season>Jan-Feb</season>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>103227</fpage>
            <pub-id pub-id-type="pmid">34563805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Facheris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jeffery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Del Duca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guttman-Yassky</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.</article-title>
            <source>Cell Mol Immunol</source>
            <year>2023</year>
            <month>May</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>448</fpage>
            <page-range>448-474</page-range>
            <pub-id pub-id-type="pmid">36928371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laidlaw</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Clinical updates in aspirin-exacerbated respiratory disease.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-6</page-range>
            <pub-id pub-id-type="pmid">30582489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Chakraborty</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <chapter-title>Asthma Medications</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30285350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shameera Ahamed</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Rajan</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Sabira</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Muraleedharan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>QSAR classification-based virtual screening followed by molecular docking studies for identification of potential inhibitors of 5-lipoxygenase.</article-title>
            <source>Comput Biol Chem</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>77</volume>
            <fpage>154</fpage>
            <page-range>154-166</page-range>
            <pub-id pub-id-type="pmid">30321850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahlin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Litonjua</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Tamari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kubo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Irvin</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Tantisira</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma.</article-title>
            <source>Pharmacogenomics J</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>665</fpage>
            <page-range>665-677</page-range>
            <pub-id pub-id-type="pmid">29298996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morina</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bo&#x000e7;ari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iljazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hyseini</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Halac</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma.</article-title>
            <source>Acta Inform Med</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-9</page-range>
            <pub-id pub-id-type="pmid">27046942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Corren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casale</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dube</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Walton-Bowen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>LaVallee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stepanians</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>178</fpage>
            <page-range>178-84</page-range>
            <pub-id pub-id-type="pmid">17718106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Zileuton</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>7</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">31643716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thalanayar Muthukrishnan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nouraie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holguin</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Zileuton use and phenotypic features in asthma.</article-title>
            <source>Pulm Pharmacol Ther</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>60</volume>
            <fpage>101872</fpage>
            <pub-id pub-id-type="pmid">31841698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddel</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Bacharier</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Brightling</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Brusselle</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Buhl</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Duijts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Drazen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mortimer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pitrez</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yorgancioglu</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Boulet</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>205</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-35</page-range>
            <pub-id pub-id-type="pmid">34658302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Popa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peltecu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gica</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ciobanu</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Botezatu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gica</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Steriade</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panaitescu</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Asthma in Pregnancy. Review of Current Literature and Recommendations.</article-title>
            <source>Maedica (Bucur)</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-87</page-range>
            <pub-id pub-id-type="pmid">34221160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Namazy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schatz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Treatment of Allergic Respiratory Disease During Pregnancy.</article-title>
            <source>J Investig Allergol Clin Immunol</source>
            <year>2016</year>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7; quiz 2p following 7</page-range>
            <pub-id pub-id-type="pmid">27012010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Zileuton</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">30000545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watkins</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Dube</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Walton-Bowen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kasten</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.</article-title>
            <source>Drug Saf</source>
            <year>2007</year>
            <volume>30</volume>
            <issue>9</issue>
            <fpage>805</fpage>
            <page-range>805-15</page-range>
            <pub-id pub-id-type="pmid">17722971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yanes</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Mosser-Goldfarb</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Emerging therapies for atopic dermatitis: The prostaglandin/leukotriene pathway.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>78</volume>
            <issue>3 Suppl 1</issue>
            <fpage>S71</fpage>
            <page-range>S71-S75</page-range>
            <pub-id pub-id-type="pmid">29248523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruno</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Spaziano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liparulo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roviezzo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nabavi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sureda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Filosa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>D'Agostino</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma.</article-title>
            <source>Eur J Med Chem</source>
            <year>2018</year>
            <month>Jun</month>
            <day>10</day>
            <volume>153</volume>
            <fpage>65</fpage>
            <page-range>65-72</page-range>
            <pub-id pub-id-type="pmid">29133059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lorenzetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vera</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ceballos</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Pisani</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Comanzo</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Tordjmann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carrillo</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Quiroga</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Participation of 5-lipoxygenase and LTB4 in liver regeneration after partial hepatectomy.</article-title>
            <source>Sci Rep</source>
            <year>2019</year>
            <month>Dec</month>
            <day>03</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>18176</fpage>
            <pub-id pub-id-type="pmid">31796842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gross</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Greos</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Meltzer</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Spangenthal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cassella</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.</article-title>
            <source>J Aerosol Med Pulm Drug Deliv</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>478</fpage>
            <page-range>478-87</page-range>
            <pub-id pub-id-type="pmid">24745666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villa-Zapata</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Lumbreras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Malone</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).</article-title>
            <source>Drug Saf</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>863</fpage>
            <page-range>863-871</page-range>
            <pub-id pub-id-type="pmid">35834155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Awni</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Hussein</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Granneman</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Cavanaugh</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1995</year>
            <volume>29 Suppl 2</volume>
            <fpage>67</fpage>
            <page-range>67-76</page-range>
            <pub-id pub-id-type="pmid">8620673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schrag</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Slaughter</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Raab</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Shou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>1352</fpage>
            <page-range>1352-60</page-range>
            <pub-id pub-id-type="pmid">14570767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granneman</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Braeckman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Cavanaugh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Awni</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Effect of zileuton on theophylline pharmacokinetics.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1995</year>
            <volume>29 Suppl 2</volume>
            <fpage>77</fpage>
            <page-range>77-83</page-range>
            <pub-id pub-id-type="pmid">8620674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cingi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Muluk</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Ipci</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>&#x0015e;ahin</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Antileukotrienes in upper airway inflammatory diseases.</article-title>
            <source>Curr Allergy Asthma Rep</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>64</fpage>
            <pub-id pub-id-type="pmid">26385352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zouboulis</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Bettoli</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Management of severe acne.</article-title>
            <source>Br J Dermatol</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>172 Suppl 1</volume>
            <fpage>27</fpage>
            <page-range>27-36</page-range>
            <pub-id pub-id-type="pmid">25597508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wenzel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Busse</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Panettieri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peters-Golden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dube</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Walton-Bowen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study.</article-title>
            <source>J Asthma</source>
            <year>2007</year>
            <month>May</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>305</fpage>
            <page-range>305-10</page-range>
            <pub-id pub-id-type="pmid">17530530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powrie</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Managing asthma in expectant mothers.</article-title>
            <source>Treat Respir Med</source>
            <year>2006</year>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">16409012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carbonara</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pacilli</surname>
                <given-names>AMG</given-names>
              </name>
              <name>
                <surname>di Palmo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nava</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Use of Symptoms Scores, Spirometry, and Other Pulmonary Function Testing for Asthma Monitoring.</article-title>
            <source>Front Pediatr</source>
            <year>2019</year>
            <volume>7</volume>
            <fpage>54</fpage>
            <pub-id pub-id-type="pmid">30891435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <article-title>Peak flow meter use in asthma management. Thoracic Society of Australia and New Zealand.</article-title>
            <source>Med J Aust</source>
            <year>1996</year>
            <month>Jun</month>
            <day>17</day>
            <volume>164</volume>
            <issue>12</issue>
            <fpage>727</fpage>
            <page-range>727-30</page-range>
            <pub-id pub-id-type="pmid">8668080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buzoianu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moiceanu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plesca</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Asthma Control Assessment in Children: Correlation between Asthma Control Test and Peak Expiratory Flow.</article-title>
            <source>Maedica (Bucur)</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>338</fpage>
            <page-range>338-43</page-range>
            <pub-id pub-id-type="pmid">25705302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brigham</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of asthma: diagnostic testing.</article-title>
            <source>Int Forum Allergy Rhinol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>5 Suppl 1</volume>
            <fpage>S27</fpage>
            <page-range>S27-30</page-range>
            <pub-id pub-id-type="pmid">26335833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gummin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Beuhler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Dibert</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Rivers</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>NPT</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>58</volume>
            <issue>12</issue>
            <fpage>1360</fpage>
            <page-range>1360-1541</page-range>
            <pub-id pub-id-type="pmid">33305966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r37">
          <label>37</label>
          <element-citation publication-type="book">
            <chapter-title>Science Brief: Evidence Used to Update the List of Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19</chapter-title>
            <collab>National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases</collab>
            <source>CDC COVID-19 Science Briefs [Internet]</source>
            <publisher-name>Centers for Disease Control and Prevention (US)</publisher-name>
            <publisher-loc>Atlanta (GA)</publisher-loc>
            <year>2022</year>
            <month>6</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">34009770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31467.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrison</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wyke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saunderson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McConnachie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Yardley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mair</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Findings from a pilot Randomised trial of an Asthma Internet Self-management Intervention (RAISIN).</article-title>
            <source>BMJ Open</source>
            <year>2016</year>
            <month>May</month>
            <day>12</day>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>e009254</fpage>
            <pub-id pub-id-type="pmid">27173807</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
